BackNovo Nordisk A/S Class B Overview
Novo Nordisk A/S Class B

Novo Nordisk A/S Class B Debt to Equity

Novo Nordisk A/S Class B (NONOF) has a debt-to-equity ratio of 0.73, above the Healthcare sector average of 0.3.

Get informed when a big investor buys or sells

+ Follow

Debt to Equity

0.73

Debt to Equity

0.73

Debt-to-Equity ratio measures a company's financial leverage by comparing its total debt to shareholder equity. A lower D/E ratio generally indicates a more financially stable company with less risk.

Debt to Equity (Comparison Companies)

Loading

Debt to Equity History

Loading

Debt to Equity Comparison

Loading

Novo Nordisk A/S Class B (NONOF) FAQ

As of the most recent data, NONOF shows a debt-to-equity ratio of 0.73. That is above the Healthcare sector average of 0.3. Scroll down for historical charts and peer comparison views.

The Healthcare sector average debt-to-equity ratio is about 0.3. Novo Nordisk A/S Class B is at 0.73, which is higher that average. That is roughly 141.2% above the sector mean. Use the comparison chart on this page to see how NONOF stacks up against individual peers as well.

Investors watch NONOF's debt-to-equity ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Novo Nordisk A/S Class B's latest reading is 0.73. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.

Besides this debt-to-equity ratio page, Stockcircle has Novo Nordisk A/S Class B's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect debt-to-equity ratio (currently 0.73) with ownership activity and broader fundamentals.

The Healthcare average debt-to-equity ratio is about 0.3, while NONOF is at 0.73. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.